Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Identifieur interne : 004539 ( Ncbi/Merge ); précédent : 004538; suivant : 004540Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Auteurs : Nobubelo K. Ngandu [Afrique du Sud] ; Jonathan M. Carlson ; Denis R. Chopera ; Nonkululeko Ndabambi ; Quarraisha Abdool Karim ; Salim Abdool Karim ; Carolyn WilliamsonSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
Descripteurs français
- KwdFr :
- Agents antiVIH (administration et posologie), Agents antiVIH (pharmacologie), Agents antiVIH (usage thérapeutique), Analyse de séquence d'ADN, Anti-infectieux (administration et posologie), Anti-infectieux (pharmacologie), Anti-infectieux (usage thérapeutique), Charge virale, Crèmes, mousses et gels vaginaux (usage thérapeutique), Essais cliniques comme sujet, Femelle, Humains, Infections à VIH (), Infections à VIH (transmission), Infections à VIH (virologie), Phylogénie, Produits du gène gag du virus de l'immunodéficience humaine (génétique), Prophylaxie pré-exposition, République d'Afrique du Sud (épidémiologie), Résultat thérapeutique, Ténofovir (usage thérapeutique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- administration et posologie : Agents antiVIH, Anti-infectieux.
- génétique : Produits du gène gag du virus de l'immunodéficience humaine, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- pharmacologie : Agents antiVIH, Anti-infectieux.
- usage thérapeutique : Agents antiVIH, Anti-infectieux, Crèmes, mousses et gels vaginaux, Infections à VIH, Ténofovir.
- virologie : Infections à VIH.
- épidémiologie : République d'Afrique du Sud.
- Analyse de séquence d'ADN, Charge virale, Essais cliniques comme sujet, Femelle, Humains, Infections à VIH, Phylogénie, Prophylaxie pré-exposition, Résultat thérapeutique, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Anti-HIV Agents (administration & dosage), Anti-HIV Agents (pharmacology), Anti-HIV Agents (therapeutic use), Anti-Infective Agents (administration & dosage), Anti-Infective Agents (pharmacology), Anti-Infective Agents (therapeutic use), Clinical Trials as Topic, Female, HIV Infections (prevention & control), HIV Infections (transmission), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (genetics), Humans, Phylogeny, Pre-Exposure Prophylaxis, Sequence Analysis, DNA, South Africa (epidemiology), Tenofovir (therapeutic use), Treatment Outcome, Vaginal Creams, Foams, and Jellies (therapeutic use), Viral Load, gag Gene Products, Human Immunodeficiency Virus (genetics).
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Anti-Infective Agents.
- chemical , genetics : gag Gene Products, Human Immunodeficiency Virus.
- chemical , pharmacology : Anti-HIV Agents, Anti-Infective Agents.
- chemical , therapeutic use : Anti-HIV Agents, Anti-Infective Agents, Tenofovir, Vaginal Creams, Foams, and Jellies.
- drug effects : HIV-1.
- epidemiology : South Africa.
- genetics : HIV-1.
- prevention & control : HIV Infections.
- transmission : HIV Infections.
- virology : HIV Infections.
- Clinical Trials as Topic, Female, Humans, Phylogeny, Pre-Exposure Prophylaxis, Sequence Analysis, DNA, Treatment Outcome, Viral Load.
Abstract
Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered genetic characteristics.
DOI: 10.1097/QAI.0000000000001458
PubMed: 28797020
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000984
- to stream PubMed, to step Curation: 000984
- to stream PubMed, to step Checkpoint: 000984
Links to Exploration step
pubmed:28797020Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.</title><author><name sortKey="Ngandu, Nobubelo K" sort="Ngandu, Nobubelo K" uniqKey="Ngandu N" first="Nobubelo K" last="Ngandu">Nobubelo K. Ngandu</name><affiliation wicri:level="1"><nlm:affiliation>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Carlson, Jonathan M" sort="Carlson, Jonathan M" uniqKey="Carlson J" first="Jonathan M" last="Carlson">Jonathan M. Carlson</name></author><author><name sortKey="Chopera, Denis R" sort="Chopera, Denis R" uniqKey="Chopera D" first="Denis R" last="Chopera">Denis R. Chopera</name></author><author><name sortKey="Ndabambi, Nonkululeko" sort="Ndabambi, Nonkululeko" uniqKey="Ndabambi N" first="Nonkululeko" last="Ndabambi">Nonkululeko Ndabambi</name></author><author><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name></author><author><name sortKey="Abdool Karim, Salim" sort="Abdool Karim, Salim" uniqKey="Abdool Karim S" first="Salim" last="Abdool Karim">Salim Abdool Karim</name></author><author><name sortKey="Williamson, Carolyn" sort="Williamson, Carolyn" uniqKey="Williamson C" first="Carolyn" last="Williamson">Carolyn Williamson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28797020</idno><idno type="pmid">28797020</idno><idno type="doi">10.1097/QAI.0000000000001458</idno><idno type="wicri:Area/PubMed/Corpus">000984</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000984</idno><idno type="wicri:Area/PubMed/Curation">000984</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000984</idno><idno type="wicri:Area/PubMed/Checkpoint">000984</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000984</idno><idno type="wicri:Area/Ncbi/Merge">004539</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.</title><author><name sortKey="Ngandu, Nobubelo K" sort="Ngandu, Nobubelo K" uniqKey="Ngandu N" first="Nobubelo K" last="Ngandu">Nobubelo K. Ngandu</name><affiliation wicri:level="1"><nlm:affiliation>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Carlson, Jonathan M" sort="Carlson, Jonathan M" uniqKey="Carlson J" first="Jonathan M" last="Carlson">Jonathan M. Carlson</name></author><author><name sortKey="Chopera, Denis R" sort="Chopera, Denis R" uniqKey="Chopera D" first="Denis R" last="Chopera">Denis R. Chopera</name></author><author><name sortKey="Ndabambi, Nonkululeko" sort="Ndabambi, Nonkululeko" uniqKey="Ndabambi N" first="Nonkululeko" last="Ndabambi">Nonkululeko Ndabambi</name></author><author><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name></author><author><name sortKey="Abdool Karim, Salim" sort="Abdool Karim, Salim" uniqKey="Abdool Karim S" first="Salim" last="Abdool Karim">Salim Abdool Karim</name></author><author><name sortKey="Williamson, Carolyn" sort="Williamson, Carolyn" uniqKey="Williamson C" first="Carolyn" last="Williamson">Carolyn Williamson</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (pharmacology)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Anti-Infective Agents (administration & dosage)</term><term>Anti-Infective Agents (pharmacology)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Female</term><term>HIV Infections (prevention & control)</term><term>HIV Infections (transmission)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Phylogeny</term><term>Pre-Exposure Prophylaxis</term><term>Sequence Analysis, DNA</term><term>South Africa (epidemiology)</term><term>Tenofovir (therapeutic use)</term><term>Treatment Outcome</term><term>Vaginal Creams, Foams, and Jellies (therapeutic use)</term><term>Viral Load</term><term>gag Gene Products, Human Immunodeficiency Virus (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (administration et posologie)</term><term>Agents antiVIH (pharmacologie)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Analyse de séquence d'ADN</term><term>Anti-infectieux (administration et posologie)</term><term>Anti-infectieux (pharmacologie)</term><term>Anti-infectieux (usage thérapeutique)</term><term>Charge virale</term><term>Crèmes, mousses et gels vaginaux (usage thérapeutique)</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (transmission)</term><term>Infections à VIH (virologie)</term><term>Phylogénie</term><term>Produits du gène gag du virus de l'immunodéficience humaine (génétique)</term><term>Prophylaxie pré-exposition</term><term>République d'Afrique du Sud (épidémiologie)</term><term>Résultat thérapeutique</term><term>Ténofovir (usage thérapeutique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>gag Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Anti-Infective Agents</term><term>Tenofovir</term><term>Vaginal Creams, Foams, and Jellies</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Produits du gène gag du virus de l'immunodéficience humaine</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Anti-infectieux</term><term>Crèmes, mousses et gels vaginaux</term><term>Infections à VIH</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>République d'Afrique du Sud</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Female</term><term>Humans</term><term>Phylogeny</term><term>Pre-Exposure Prophylaxis</term><term>Sequence Analysis, DNA</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de séquence d'ADN</term><term>Charge virale</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Infections à VIH</term><term>Phylogénie</term><term>Prophylaxie pré-exposition</term><term>Résultat thérapeutique</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered genetic characteristics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28797020</PMID><DateCreated><Year>2017</Year><Month>08</Month><Day>10</Day></DateCreated><DateCompleted><Year>2017</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.</ArticleTitle><Pagination><MedlinePgn>43-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000001458</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered genetic characteristics.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The participants of the CAPRISA 004 trial (n = 28 TFV and 43 placebo) were from KwaZulu-Natal Province, South Africa and were infected with HIV-1 subtype C. After HIV-1 diagnosis, they were recruited into the CAPRISA 002 cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed gag sequences from the earliest time point post infection (within 3 months of estimated time of infection). Transmission index was measured using a model which predicts the likelihood of an amino acid to be transmitted. Phylogenetic distance from a regional consensus sequence was calculated from a maximum likelihood phylogenetic tree.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Transmission index and distance from the most common (consensus) sequence have been shown to be markers of transmission fitness. We found that viruses infecting TFV gel recipients were closer to the consensus sequence of regional strains (P = 0.003) and had higher transmission index (P = 0.01). The transmission index was weakly correlated with concomitant viral load (Spearman r = 0.22, P = 0.06).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Decreased acquisition risk may have increased the barrier to infection therefore selecting for fitter, more consensus-like viruses. Such virus fitness effects will need to be considered for future pre-exposure prophylaxis and vaccine trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ngandu</LastName><ForeName>Nobubelo K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Chopera</LastName><ForeName>Denis R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Ndabambi</LastName><ForeName>Nonkululeko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Abdool Karim</LastName><ForeName>Quarraisha</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Abdool Karim</LastName><ForeName>Salim</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI051794</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014622">Vaginal Creams, Foams, and Jellies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054301">gag Gene Products, Human Immunodeficiency Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS Comput Biol. 2014 Aug 07;10(8):e1003776</RefSource><PMID Version="1">25102049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genetics. 1995 Dec;141(4):1641-50</RefSource><PMID Version="1">8601501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2010 Sep 3;329(5996):1168-74</RefSource><PMID Version="1">20643915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2015 Sep 17;11(9):e1005154</RefSource><PMID Version="1">26378795</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010 Feb 19;5(2):e9310</RefSource><PMID Version="1">20174579</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunity. 2013 Mar 21;38(3):606-17</RefSource><PMID Version="1">23521886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61</RefSource><PMID Version="1">25247433</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Jul 1;206(1):35-40</RefSource><PMID Version="1">22551813</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biol Evol. 2013 Dec;30(12):2725-9</RefSource><PMID Version="1">24132122</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2016 May 10;12 (5):e1005619</RefSource><PMID Version="1">27163788</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2007 Oct;81(19):10625-35</RefSource><PMID Version="1">17634235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2014 Jul 11;345(6193):1254031</RefSource><PMID Version="1">25013080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2015 Apr 15;211(8):1211-8</RefSource><PMID Version="1">25587020</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2005 Mar 1;21(5):676-9</RefSource><PMID Version="1">15509596</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Aug 11;365(6):493-505</RefSource><PMID Version="1">21767103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Syst Biol. 2003 Oct;52(5):696-704</RefSource><PMID Version="1">14530136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2015 Sep 1;212(5):754-9</RefSource><PMID Version="1">25712973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2012;8(11):e1003041</RefSource><PMID Version="1">23209412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Feb 1;205(3):358-65</RefSource><PMID Version="1">22241800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7</RefSource><PMID Version="1">22362152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2011 Apr 6;3(77):77ra29</RefSource><PMID Version="1">21471433</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Nov;206(9):1433-42</RefSource><PMID Version="1">22997233</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2009 Feb 15;199(4):580-9</RefSource><PMID Version="1">19143562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2016 Jun;22(6):606-13</RefSource><PMID Version="1">27183217</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11030-5</RefSource><PMID Version="1">15258291</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2004 Dec 9;432(7018):769-75</RefSource><PMID Version="1">15592417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epidemics. 2009 Dec;1(4):230-9</RefSource><PMID Version="1">21352769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Elife. 2015 Dec 11;4:null</RefSource><PMID Version="1">26652000</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Aug 28;8(8):e71758</RefSource><PMID Version="1">24015191</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2011 Aug 17;477(7362):95-8</RefSource><PMID Version="1">21849975</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2010 Nov;84(22):11937-49</RefSource><PMID Version="1">20810731</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="N">Pre-Exposure Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014622" MajorTopicYN="N">Vaginal Creams, Foams, and Jellies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054301" MajorTopicYN="N">gag Gene Products, Human Immunodeficiency Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28797020</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000001458</ArticleId><ArticleId IdType="pii">00126334-201709010-00006</ArticleId><ArticleId IdType="pmc">PMC5576519</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li></country></list><tree><noCountry><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name><name sortKey="Abdool Karim, Salim" sort="Abdool Karim, Salim" uniqKey="Abdool Karim S" first="Salim" last="Abdool Karim">Salim Abdool Karim</name><name sortKey="Carlson, Jonathan M" sort="Carlson, Jonathan M" uniqKey="Carlson J" first="Jonathan M" last="Carlson">Jonathan M. Carlson</name><name sortKey="Chopera, Denis R" sort="Chopera, Denis R" uniqKey="Chopera D" first="Denis R" last="Chopera">Denis R. Chopera</name><name sortKey="Ndabambi, Nonkululeko" sort="Ndabambi, Nonkululeko" uniqKey="Ndabambi N" first="Nonkululeko" last="Ndabambi">Nonkululeko Ndabambi</name><name sortKey="Williamson, Carolyn" sort="Williamson, Carolyn" uniqKey="Williamson C" first="Carolyn" last="Williamson">Carolyn Williamson</name></noCountry><country name="Afrique du Sud"><noRegion><name sortKey="Ngandu, Nobubelo K" sort="Ngandu, Nobubelo K" uniqKey="Ngandu N" first="Nobubelo K" last="Ngandu">Nobubelo K. Ngandu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004539 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004539 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28797020
|texte= Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28797020" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |